Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Current Leases: 2023-2025

Historic Current Leases for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $633,000.

  • Compass Therapeutics' Current Leases rose 13.64% to $633,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $633,000, marking a year-over-year increase of 13.64%. This contributed to the annual value of $338,000 for FY2024, which is 71.76% down from last year.
  • Per Compass Therapeutics' latest filing, its Current Leases stood at $633,000 for Q3 2025, which was up 133.58% from $271,000 recorded in Q2 2025.
  • Over the past 5 years, Compass Therapeutics' Current Leases peaked at $1.2 million during Q1 2024, and registered a low of $109,000 during Q1 2025.
  • For the 3-year period, Compass Therapeutics' Current Leases averaged around $805,455, with its median value being $1.1 million (2024).
  • The largest annual percentage gain for Compass Therapeutics' Current Leases in the last 5 years was 13.64% (2025), contrasted with its biggest fall of 91.09% (2025).
  • Quarterly analysis of 3 years shows Compass Therapeutics' Current Leases stood at $1.2 million in 2023, then tumbled by 71.76% to $338,000 in 2024, then grew by 13.64% to $633,000 in 2025.
  • Its Current Leases was $633,000 in Q3 2025, compared to $271,000 in Q2 2025 and $109,000 in Q1 2025.